Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1976 Sep;39(9):870–876. doi: 10.1136/jnnp.39.9.870

Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.

P Ettigi, N P Nair, S Lal, P Cervantes, H Guyda
PMCID: PMC492475  PMID: 993808

Abstract

Serum growth hormone (GH) and prolactin (PRL) concentrations were measured after administration of the dopamine receptor agonist, apomorphine HC1 (0.75 mg subcutaneously), to 17 chronic schizophrenic patients, four of whom had an oral dyskinesia, who were withdrawn from chronic neuroleptic therapy for periods of two to 15 weeks, and in 21 control subjects (normal volunteers or physically healthy alcoholics not exposed to neuroleptics). Six of the schizophrenic patients, but none of the controls, had raised baseline levels of GH (greater than 6 ng/ml). After apomorphine all controls showed an increase in serum GH with a peak concentration of 9 ng/ml or more, whereas eight subjects withdrawn from neuroleptics showed an inadequate response (peak less than 6 ng/ml) and in two others an inadequate response was obtained on one of two trials. The peak GH concentration was significantly less after apomorphine in patients withdrawn from neuroleptics (11.90 +/- 3.19 ng/ml) compared with controls (20.80 +/- 2.11 ng/ml) (P less than 0.05). Among patients withdrawn from neuroleptics, those with an oral dyskinesia had significantly lower peak GH concentration 2.46 +/- 0.93 ng/ml) after apomorphine compared with those without (14.85 +/- 3.83 ng/ml) (P less than 0.05). There were no differences in serum PRL concentrations, before or after apomorphine administration, between patients withdrawn from neuroleptics and controls. In uncontrolled observations none of the four patients with an oral dyskinesia showed any worsening of the movement disorder after apomorphine. These data provide no evidence for supersensitivity of dopamine receptors in chronic schizophrenic patients withdrawn from chronic neuroleptic therapy.

Full text

PDF
870

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angrist B., Sathananthan G., Gershon S. Behavioral effects of L-dopa in schizophrenic patients. Psychopharmacologia. 1973 Jul 4;31(1):1–12. doi: 10.1007/BF00429294. [DOI] [PubMed] [Google Scholar]
  2. Braham J., Sarova-Pinhas I., Goldhammer Y. Apomorphine in Parkinsonian tremor. Br Med J. 1970 Sep 26;3(5725):768–768. doi: 10.1136/bmj.3.5725.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daughaday W. H., Jacobs L. S. Human prolactin. Ergeb Physiol. 1972;67:169–194. doi: 10.1007/BFb0036329. [DOI] [PubMed] [Google Scholar]
  4. Düby S. E., Cotzias G. C., Papavasiliou P. S., Lawrence W. H. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol. 1972 Dec;27(6):474–480. doi: 10.1001/archneur.1972.00490180010004. [DOI] [PubMed] [Google Scholar]
  5. Ettigi P., Lal S., Martin J. B., Friesen H. G. Effectof sex, oral contraceptives, and glucose loading on apomorphine-induced growth hormone secretion. J Clin Endocrinol Metab. 1975 Jun;40(6):1094–1098. doi: 10.1210/jcem-40-6-1094. [DOI] [PubMed] [Google Scholar]
  6. Feighner J. P., Robins E., Guze S. B., Woodruff R. A., Jr, Winokur G., Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972 Jan;26(1):57–63. doi: 10.1001/archpsyc.1972.01750190059011. [DOI] [PubMed] [Google Scholar]
  7. Friesen H., Guyda H., Hardy J. The biosynthesis of human growth hormone and prolactin. J Clin Endocrinol Metab. 1970 Dec;31(6):611–624. doi: 10.1210/jcem-31-6-611. [DOI] [PubMed] [Google Scholar]
  8. Gianutsos G., Drawbaugh R. B., Hynes M. D., Lal H. Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 1974 Mar 1;14(5):887–898. doi: 10.1016/0024-3205(74)90078-2. [DOI] [PubMed] [Google Scholar]
  9. Hwang P., Guyda H., Friesen H. A radioimmunoassay for human prolactin. Proc Natl Acad Sci U S A. 1971 Aug;68(8):1902–1906. doi: 10.1073/pnas.68.8.1902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Klawans H. L., Jr, Goetz C., Westheimer R. Pathophysiology of schizophrenia and the striatum. Dis Nerv Syst. 1972 Nov;33(11):711–719. [PubMed] [Google Scholar]
  11. Korenyi C., Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst. 1968 Dec;29(12):827–828. [PubMed] [Google Scholar]
  12. Lal S., De la Vega C. E., Sourkes T. L., Friesen H. G. Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. J Clin Endocrinol Metab. 1973 Nov;37(5):719–724. doi: 10.1210/jcem-37-5-719. [DOI] [PubMed] [Google Scholar]
  13. Lal S., De la Vega C. E., Sourkes T. L., Friesen H. G. Effect of apomorphine on human-growth-hormone secretion. Lancet. 1972 Sep 23;2(7778):661–661. doi: 10.1016/s0140-6736(72)93061-9. [DOI] [PubMed] [Google Scholar]
  14. Lal S., Martin J. B., De la Vega C. E., Friesen H. G. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men. Clin Endocrinol (Oxf) 1975 May;4(3):277–285. doi: 10.1111/j.1365-2265.1975.tb01535.x. [DOI] [PubMed] [Google Scholar]
  15. Lal S., Tolis G., Martin S. B., Brown G. M., Guyda H. Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone in the serum of normal men. J Clin Endocrinol Metab. 1975 Nov;41(5):827–832. doi: 10.1210/jcem-41-5-827. [DOI] [PubMed] [Google Scholar]
  16. Maany I., Frazer A., Mendels J. Apomorphine: effect on growth hormone. J Clin Endocrinol Metab. 1975 Jan;40(1):162–163. doi: 10.1210/jcem-40-1-162. [DOI] [PubMed] [Google Scholar]
  17. Martin J. B., Lal S., Tolis G., Friesen H. G. Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin. J Clin Endocrinol Metab. 1974 Jul;39(1):180–182. doi: 10.1210/jcem-39-1-180. [DOI] [PubMed] [Google Scholar]
  18. Martin J. B. Neural regulation of growth hormone secretion. N Engl J Med. 1973 Jun 28;288(26):1384–1393. doi: 10.1056/NEJM197306282882606. [DOI] [PubMed] [Google Scholar]
  19. Randrup A., Munkvad I. Pharmacology and physiology of stereotyped behavior. J Psychiatr Res. 1974;11:1–10. doi: 10.1016/0022-3956(74)90062-4. [DOI] [PubMed] [Google Scholar]
  20. Rivera J. L., Lal S., Ettigi P., Hontela S., Muller H. F., Friesen H. G. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976 May;5(3):273–282. doi: 10.1111/j.1365-2265.1976.tb01953.x. [DOI] [PubMed] [Google Scholar]
  21. Rubovits R., Klawans H. L., Jr Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias. Arch Gen Psychiatry. 1972 Oct;27(4):502–507. doi: 10.1001/archpsyc.1972.01750280070012. [DOI] [PubMed] [Google Scholar]
  22. Schimmelbusch W. H., Mueller P. S., Sheps J. The positive correlation between insulin resistance and duration of hospitalization in untreated schizophrenia. Br J Psychiatry. 1971 Apr;118(545):429–436. doi: 10.1192/bjp.118.545.429. [DOI] [PubMed] [Google Scholar]
  23. Tarsy D., Baldessarini R. J. Pharmacologically induced behavioural supersensitivity to apomorphine. Nat New Biol. 1973 Oct 31;245(148):262–263. doi: 10.1038/newbio245262a0. [DOI] [PubMed] [Google Scholar]
  24. Vigneri R., Pezzino V., Squatrito S., Calandra A., Maricchiolo M. Sleep-associated growth hormone (GH) release in schizophrenia. Neuroendocrinology. 1974;14(6):356–361. doi: 10.1159/000122280. [DOI] [PubMed] [Google Scholar]
  25. Vonvoigtlander P. F., Losey E. G., Triezenberg H. J. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther. 1975 Apr;193(1):88–94. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES